[go: up one dir, main page]

PE20130231A1 - Dispersiones solidas del compuesto n-(4-{4-amino-7-[1-(2-hidroxietil)-1h-pirazol-4-il]tieno[3,2-c]piridin-3-il}fenil)-n'-(3-fluorofenil)urea - Google Patents

Dispersiones solidas del compuesto n-(4-{4-amino-7-[1-(2-hidroxietil)-1h-pirazol-4-il]tieno[3,2-c]piridin-3-il}fenil)-n'-(3-fluorofenil)urea

Info

Publication number
PE20130231A1
PE20130231A1 PE2012002285A PE2012002285A PE20130231A1 PE 20130231 A1 PE20130231 A1 PE 20130231A1 PE 2012002285 A PE2012002285 A PE 2012002285A PE 2012002285 A PE2012002285 A PE 2012002285A PE 20130231 A1 PE20130231 A1 PE 20130231A1
Authority
PE
Peru
Prior art keywords
compound
present
pirazol
pyridin
fluorophenyl
Prior art date
Application number
PE2012002285A
Other languages
English (en)
Inventor
Jonathan Miller
Rajeev Gokhale
Eric A Schmitt
Yi Gao
Justin Lafountaine
Lloyd Dias
Original Assignee
Abbvie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44475097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130231(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Bahamas Ltd filed Critical Abbvie Bahamas Ltd
Publication of PE20130231A1 publication Critical patent/PE20130231A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE REFIERE A UN PRODUCTO EN DISPERSION SOLIDA QUE COMPRENDE: A) UN COMPUESTO INHIBIDOR DE QUINASA TAL COMO N-(4-{4-AMINO-7-[1-(2-HIDROXIETIL)-1H-PIRAZOL-4-IL]TIENO[3,2-c]PIRIDIN-3-IL}FENIL)-N´-(3-FLUOROFENIL)UREA, PRESENTE ENTRE 1% A 40% EN PESO EQUIVALENTE A LA BASE LIBRE; B) UN ACIDO TAL COMO ACIDO ACETICO, ACIDO LACTICO, ACIDO SUCCINICO, ENTRE OTROS, PRESENTE ENTRE 0,1 A 10 EQUIVALENTES CON RESPECTO AL COMPUESTO INHIBIDOR DE QUINASA; C) UN VEHICULO POLIMERICO TAL COMO HOMOPOLIMEROS Y COPOLIMEROS DE N-VINIL LACTAMAS, ESTERES DE CELULOSA, ENTRE OTROS, PRESENTE ENTRE 40% A 85% EN PESO Y D) UN TENSIOACTIVO TAL COMO POLISORBATOS, MONOESTERES DE SORBITAN, SUCCINATO DE GLICOL, ENTRE OTROS, PRESENTE ENTRE 5% A 30% EN PESO. REFERIDO ADEMAS UN PROCESO DE PREPARACION. DICHO COMPUESTO ES UTIL PARA EL TRATAMIENTO DE CANCER.DCI: ILORASERTIB
PE2012002285A 2010-06-09 2011-06-07 Dispersiones solidas del compuesto n-(4-{4-amino-7-[1-(2-hidroxietil)-1h-pirazol-4-il]tieno[3,2-c]piridin-3-il}fenil)-n'-(3-fluorofenil)urea PE20130231A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35286210P 2010-06-09 2010-06-09

Publications (1)

Publication Number Publication Date
PE20130231A1 true PE20130231A1 (es) 2013-04-04

Family

ID=44475097

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012002285A PE20130231A1 (es) 2010-06-09 2011-06-07 Dispersiones solidas del compuesto n-(4-{4-amino-7-[1-(2-hidroxietil)-1h-pirazol-4-il]tieno[3,2-c]piridin-3-il}fenil)-n'-(3-fluorofenil)urea

Country Status (28)

Country Link
US (1) US8557995B2 (es)
EP (1) EP2579855B1 (es)
JP (1) JP5758486B2 (es)
KR (1) KR20130109092A (es)
CN (1) CN103002880B (es)
AR (1) AR081845A1 (es)
AU (1) AU2011264993B2 (es)
BR (1) BR112012031516A2 (es)
CA (1) CA2802021A1 (es)
CL (1) CL2012003446A1 (es)
CO (1) CO6640325A2 (es)
CR (1) CR20120647A (es)
DO (1) DOP2012000306A (es)
EC (1) ECSP13012364A (es)
ES (1) ES2523999T3 (es)
GT (1) GT201200333A (es)
HK (1) HK1182327A1 (es)
MX (1) MX2012014387A (es)
NZ (1) NZ605434A (es)
PE (1) PE20130231A1 (es)
PH (1) PH12012502432A1 (es)
RU (1) RU2566716C2 (es)
SG (2) SG186248A1 (es)
TW (1) TW201202234A (es)
UA (1) UA108886C2 (es)
UY (1) UY33437A (es)
WO (1) WO2011156361A2 (es)
ZA (1) ZA201300108B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2857337A1 (en) * 2011-12-14 2013-06-20 Abbvie Inc. Compositions containing kinase inhibitors
WO2014024210A2 (en) * 2012-08-10 2014-02-13 Hetero Research Foundation Novel polymorphs of doxercalciferol
KR101986683B1 (ko) * 2012-12-13 2019-06-10 한미약품 주식회사 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
US9249134B2 (en) * 2013-03-26 2016-02-02 Cadila Healthcare Limited Process for preparation of amorphous form of dasatinib
EP3021836B1 (en) * 2013-07-19 2020-10-07 Siga Technologies Inc. Amorphous tecovirimat preparation
KR20160104709A (ko) 2013-12-31 2016-09-05 아센디아 파마슈티컬스, 엘엘씨 난수용성 화합물용 약제학적 조성물
WO2015141662A1 (ja) * 2014-03-18 2015-09-24 武田薬品工業株式会社 固体分散体
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
WO2015200635A1 (en) * 2014-06-25 2015-12-30 Abbvie Inc. N-(4-{4-AMINO-7-[1-(2-HYDROXYETHYL)-1H-PYRAZOL-4-yl]THIENO[3,2-c]PYRIDIN-3-YL}PHENYL)-N'-(3-FLUOROPHENYL)UREA DOCUSATE
MX376083B (es) 2015-06-04 2025-03-07 Pfizer Formas de dosificacion solidas de palbociclib.
US10449195B2 (en) * 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN109078006B (zh) * 2016-03-29 2021-04-20 深圳市药欣生物科技有限公司 一种帕布昔利布的药物制剂及其制备方法
EP3936127A4 (en) 2019-03-04 2022-12-14 Japan Tobacco Inc. Amorphous solid dispersion of pyrazole-amide compound
CN110946829A (zh) * 2019-12-30 2020-04-03 上海景峰制药有限公司 一种阿瑞匹坦固体分散体及其制备方法和应用
AU2021210974A1 (en) 2020-01-24 2022-09-22 Nanocopoeia, Llc Amorphous solid dispersions of dasatinib and uses thereof
AU2021212258A1 (en) 2020-01-31 2022-09-29 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
EP4142699A1 (en) 2020-04-30 2023-03-08 Nanocopoeia LLC Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
CA3203975A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
EP4320233A1 (en) 2021-04-07 2024-02-14 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2023283616A1 (en) * 2021-07-09 2023-01-12 Regents Of The University Of Minnesota Amorphous solid dispersion of sorafenib and solid formualtion comprising the same
NL2028762B1 (en) * 2021-07-16 2023-01-23 Seranovo Holding B V Micelle-generating formulations for enhanced bioavailability
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
RU2316326C2 (ru) * 2001-12-03 2008-02-10 Байер Фамэсьютиклс Копэрейшн Способ и композиция для лечения ракового заболевания, тозилат и фармацевтически приемлемые соли n-(4-хлор-3-(трифторметил)фенил)-n'-(4-(2-(n-метилкарбамоил)-4-пиридилокси)фенил)мочевины
RS67304A (en) 2002-02-01 2006-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
MXPA04007428A (es) 2002-02-01 2004-10-11 Pfizer Prod Inc Formas de dosificacion de liberacion inmediata que contienen dispersiones de farmaco solido.
RS61604A (en) 2002-02-01 2006-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
US7202363B2 (en) 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
MX2007002398A (es) 2004-08-27 2007-05-15 Bayer Pharmaceuticals Corp Nuevas composiciones farmaceuticas para el tratamiento de cancer.
US8834929B2 (en) 2006-07-21 2014-09-16 Bend Research, Inc. Drying of drug-containing particles
JP2010509289A (ja) * 2006-11-09 2010-03-25 アボット ゲーエムベーハー ウント コンパニー カーゲー チロシンキナーゼ阻害剤の経口投与用薬学的剤形
JP2011500649A (ja) * 2007-10-19 2011-01-06 アボット ゲーエムベーハー ウント カンパニー カーゲー Ｎ−アリール尿素系薬剤の固体分散体生成物
UA106878C2 (uk) 2008-10-07 2014-10-27 Астразенека Юк Лімітед Фармацевтична композиція, що містить 4-[3-(4-циклопропанкарбонілпіперазин-1-карбоніл)-4-фторбензил]-2н-фталазин-1-он або його сіль, або сольват, у твердій дисперсії з матричним полімером коповідоном
KR101639642B1 (ko) * 2008-12-05 2016-07-14 애브비 바하마스 리미티드 암 치료에 사용하기 위한 키나제 억제제로서의 티에노［3,2-ｃ］피리딘 유도체
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑

Also Published As

Publication number Publication date
HK1182327A1 (en) 2013-11-29
PH12012502432A1 (en) 2013-02-11
RU2012156254A (ru) 2014-07-20
AU2011264993A1 (en) 2013-01-24
NZ605434A (en) 2014-03-28
MX2012014387A (es) 2013-05-01
DOP2012000306A (es) 2013-01-31
GT201200333A (es) 2014-06-10
WO2011156361A2 (en) 2011-12-15
JP5758486B2 (ja) 2015-08-05
UA108886C2 (ru) 2015-06-25
SG186248A1 (en) 2013-01-30
CN103002880A (zh) 2013-03-27
KR20130109092A (ko) 2013-10-07
TW201202234A (en) 2012-01-16
EP2579855A2 (en) 2013-04-17
ZA201300108B (en) 2013-09-25
US20110306632A1 (en) 2011-12-15
CL2012003446A1 (es) 2013-04-05
BR112012031516A2 (pt) 2016-11-08
AU2011264993B2 (en) 2014-02-06
CA2802021A1 (en) 2011-12-15
ES2523999T3 (es) 2014-12-03
RU2566716C2 (ru) 2015-10-27
WO2011156361A3 (en) 2012-07-05
AR081845A1 (es) 2012-10-24
US8557995B2 (en) 2013-10-15
ECSP13012364A (es) 2013-01-31
JP2013528218A (ja) 2013-07-08
CR20120647A (es) 2013-04-08
CO6640325A2 (es) 2013-03-22
SG2014013502A (en) 2014-05-29
UY33437A (es) 2012-01-31
EP2579855B1 (en) 2014-09-03
CN103002880B (zh) 2015-01-28

Similar Documents

Publication Publication Date Title
PE20130231A1 (es) Dispersiones solidas del compuesto n-(4-{4-amino-7-[1-(2-hidroxietil)-1h-pirazol-4-il]tieno[3,2-c]piridin-3-il}fenil)-n'-(3-fluorofenil)urea
PE20151335A1 (es) Composicion farmaceutica con biodisponibilidad mejorada
AU2016213805A1 (en) Nuclear transport modulators and uses thereof
EP4234545A3 (en) Hydrazide containing nuclear transport modulators and uses thereof
NZ601121A (en) 5-alkynyl-pyrimidines
NZ626505A (en) Substituted pyrrolidine-2-carboxamides
BR112018007864A2 (pt) métodos para preparar células t para terapia de células t
PE20142343A1 (es) Compuesto pirazol y su uso farmaceutico
PE20150726A1 (es) Compuestos y composiciones que modulan la actividad del receptor del factor de crecimiento epidermico (egfr)
PH12012501772A1 (en) N-(imidazopyrimidin-7-yl)-heteroarylamide derivatives and their use as pde10a inhibitors
IN2014MN00258A (es)
MX2010007587A (es) Compuestos que comprenden un grupo ciclobutoxi.
MX2012008260A (es) Novedosos derivados de triazol sustituidos como moduladores de la gamma secretasa.
MX2014004955A (es) Amida de acido n-(tetrazol-5-il)arilcarboxilico y amida de n-(triazol-5-il)arilcarboxilico sustituidas con 5-fenilo y uso de las mismas como herbicidas.
PH12014502465A1 (en) Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists
PE20150194A1 (es) Novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa
NZ610378A (en) Lipoyl compounds and their use for treating ischemic injury
MX2012006022A (es) Compuestos novedosos como moduladores de receptor con utilidad terapeutica.
PE20140966A1 (es) Quinazolincarboxamida azetidinas
WO2012066488A3 (en) Bridged spiro[2.4]heptane ester derivatives
MX2014011188A (es) Compuestos y metodos para el tratamiento de trastornos celulares adrenocorticales aberrantes.
MX2013001965A (es) Compuestos disustituidos de tetrahidrofuranilo como antagonistas de receptor de bradiquinina b1
NZ709362A (en) Process for the preparation of 1-([1,3]dioxolan-4-ylmethyl)-1h-pyrazol-3-ylamine
CR20140433A (es) Nuevas formas cristalinas polimorficas de 5-(2-{[6-(2,2-difluoro -2-feniletoxi) hexil] amino}-1-(r)-hidroxietil)-8-hidroxiquinolin-2 (1h)-ona, heminapadisilato como agonista del receptor adrenergico b2
GEP20156395B (en) Synthesis process, and crystalline form of 4-{3-[cis-hexahydrocyclopenta[c]pyrr ol-2(1h)-yl]propoxy}benzamide hydrochloride and pharmaceutical compositions containing thereof

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed